Stock 2616 CSTONE PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

Consensus CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
0.9 HKD -2.17% Intraday chart for CStone Pharmaceuticals +4.65% -60.35%
Apr. 24 Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5% MT
Apr. 23 CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on CStone Pharmaceuticals

Price target over the last 5 years

History of analyst recommendation changes

578fbb9426eff6229874666e6.GIsh8nx-bRkU258l0NRR1RMz4WMcg5wvZVHnck-UK8k.TLlWik4OP3wsmslol4IUkEwKkSFT2cxHBB6_NS7yQ5tqwGDESTc8cCyP8A~ef003c4ed972708c45ad92011dfd7f9f

Analyst Recommendations on CStone Pharmaceuticals

CStone Pharma's Investigational Antibody Boosts Objective Response Rate of Lymphoma Patients in Clinical Trial MT
CStone Announces Phase 2 GEMSTONE-201 Trial Met Primary Endpoint of Objective Response Rate in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) CI
CStone's Anti-PD-L1 Antibody Demonstrates a Complete Response Rate of 31.8% in Patients With Relapsed or Refractory Extra nodal Natural Killer/T-Cell Lymphoma CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8329 CNY
Average target price
3.186 CNY
Spread / Average Target
+282.57%
High Price Target
3.675 CNY
Spread / Highest target
+341.22%
Low Price Target
2.698 CNY
Spread / Lowest Target
+223.92%

Consensus detail

Consensus revision (last 18 months)

Ratings for CStone Pharmaceuticals

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 2616 Stock
  4. Consensus CStone Pharmaceuticals